BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eloubeidi MA, Desmond RA, Wilcox CM, Wilson RJ, Manchikalapati P, Fouad MM, Eltoum I, Vickers SM. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006;192:322-329. [PMID: 16920426 DOI: 10.1016/j.amjsurg.2006.02.017] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Domínguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, Fernández-Del Castillo C. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg. 2008;32:1051-1056. [PMID: 18224462 DOI: 10.1007/s00268-007-9423-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
2 Khawja SN, Mohammed S, Silberfein EJ, Musher BL, Fisher WE, Van Buren G 2nd. Pancreatic cancer disparities in African Americans. Pancreas. 2015;44:522-527. [PMID: 25872128 DOI: 10.1097/mpa.0000000000000323] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
3 Krishnaraju VS, Kumar R, Mittal BR, Sharma V, Singh H, Nada R, Bal A, Rohilla M, Singh H, Rana SS. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue. Eur Radiol 2021;31:2199-208. [PMID: 33001304 DOI: 10.1007/s00330-020-07318-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Atkins JJ, Fiala MA, Wang-Gillam A, Wildes TM. Racial Disparities in the Outcomes of Patients With Stage IV Pancreatic Adenocarcinoma Are Mediated by Chemotherapy Utilization. Pancreas 2016;45:e33-4. [PMID: 27400157 DOI: 10.1097/MPA.0000000000000618] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Bjerregaard JK, Mortensen MB, Schønnemann KR, Pfeiffer P. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer 2013;49:98-105. [PMID: 22909997 DOI: 10.1016/j.ejca.2012.07.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
6 Rauh-hain JA, Buskwofie A, Clemmer J, Boruta DM, Schorge JO, del Carmen MG. Racial Disparities in Treatment of High-Grade Endometrial Cancer in the Medicare Population. Obstetrics & Gynecology 2015;125:843-51. [DOI: 10.1097/aog.0000000000000605] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
7 Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636-46; discussion 1646. [PMID: 17912593 DOI: 10.1007/s11605-007-0315-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
8 Oberstein PE, Hershman DL, Khanna LG, Chabot JA, Insel BJ, Neugut AI. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study. Cancer Invest 2013;31:316-22. [PMID: 23614655 DOI: 10.3109/07357907.2013.789904] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
9 David M, Lepage C, Jouve JL, Jooste V, Chauvenet M, Faivre J, Bouvier AM. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer. 2009;101:215-218. [PMID: 19568238 DOI: 10.1038/sj.bjc.6605150] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
10 Torres MB, Dixon MEB, Gusani NJ. Undertreatment of Pancreatic Cancer: The Intersection of Bias, Biology, and Geography. Surg Oncol Clin N Am 2022;31:43-54. [PMID: 34776063 DOI: 10.1016/j.soc.2021.07.006] [Reference Citation Analysis]
11 Takahashi N, Fukushima T, Yorita K, Tanaka H, Chijiiwa K, Kataoka H. Dickkopf-1 is overexpressed in human pancreatic ductal adenocarcinoma cells and is involved in invasive growth. Int J Cancer. 2010;126:1611-1620. [PMID: 19711349 DOI: 10.1002/ijc.24865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 0.6] [Reference Citation Analysis]
12 Dumbrava MI, Burmeister EA, Wyld D, Goldstein D, O'connell DL, Beesley VL, Gooden HM, Janda M, Jordan SJ, Merrett ND, Payne ME, Waterhouse MA, Neale RE. Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. Asia-Pac J Clin Oncol 2018;14:326-36. [DOI: 10.1111/ajco.12862] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Lee S, Reha JL, Tzeng CW, Massarweh NN, Chang GJ, Hetz SP, Fleming JB, Lee JE, Katz MH. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol 2013;20:4073-9. [PMID: 24002535 DOI: 10.1245/s10434-013-3130-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
14 Kagedan DJ, Abraham L, Goyert N, Li Q, Paszat LF, Kiss A, Earle CC, Mittmann N, Coburn NG. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer: Marginalization and Pancreatic Cancer. Cancer 2016;122:3175-82. [DOI: 10.1002/cncr.30148] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
15 Burmeister E, Waterhouse M, Jordan S, O'connell D, Merrett N, Goldstein D, Wyld D, Beesley V, Gooden H, Janda M, Neale R. Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. Pancreatology 2016;16:873-81. [DOI: 10.1016/j.pan.2016.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lee BM, Chung SY, Chang JS, Lee KJ, Seong J. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy. Gut Liver 2018;12:342-52. [PMID: 29409306 DOI: 10.5009/gnl17216] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
17 Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008;196:430-41. [PMID: 18718222 DOI: 10.1016/j.amjsurg.2008.04.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
18 Fitzgerald TL, Bradley CJ, Dahman B, Zervos EE. Gastrointestinal malignancies: when does race matter? J Am Coll Surg 2009;209:645-52. [PMID: 19854407 DOI: 10.1016/j.jamcollsurg.2009.08.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
19 Tomasello G, Ghidini M, Costanzo A, Ghidini A, Russo A, Barni S, Passalacqua R, Petrelli F. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. J Gastrointest Oncol. 2019;10:259-269. [PMID: 31032093 DOI: 10.21037/jgo.2018.12.08] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
20 Lim KH, Langley E, Gao F, Luo J, Li L, Meyer G, Kim P, Singh S, Kushnir VM, Early DS, Mullady DK, Edmundowicz SA, Wani S, Murad FM, Cao D, Azar RR, Wang-Gillam A. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget 2017;8:24250-61. [PMID: 28445954 DOI: 10.18632/oncotarget.15653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, Davis M, de Smith AJ, Dutil J, Figueiredo JC, Fox R, Graves KD, Gomez SL, Llera A, Neuhausen SL, Newman L, Nguyen T, Palmer JR, Palmer NR, Pérez-Stable EJ, Piawah S, Rodriquez EJ, Sanabria-Salas MC, Schmit SL, Serrano-Gomez SJ, Stern MC, Weitzel J, Yang JJ, Zabaleta J, Ziv E, Fejerman L. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer 2021;124:315-32. [PMID: 32901135 DOI: 10.1038/s41416-020-01038-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 24.0] [Reference Citation Analysis]
22 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
23 Wilcox CM, Kim H, Seay T, Varadarajulu S. Choice of plastic or metal stent for patients with jaundice with pancreaticobiliary malignancy using simple clinical tools: a prospective evaluation. BMJ Open Gastroenterol 2015;2:e000014. [PMID: 26462270 DOI: 10.1136/bmjgast-2014-000014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Eloubeidi MA, Varadarajulu S, Desai S, Shirley R, Heslin MJ, Mehra M, Arnoletti JP, Eltoum I, Wilcox CM, Vickers SM. A prospective evaluation of an algorithm incorporating routine preoperative endoscopic ultrasound-guided fine needle aspiration in suspected pancreatic cancer. J Gastrointest Surg. 2007;11:813-819. [PMID: 17440790 DOI: 10.1007/s11605-007-0151-x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 5.7] [Reference Citation Analysis]
25 Grant WB, Peiris AN. Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. Dermatoendocrinol 2012;4:85-94. [PMID: 22928063 DOI: 10.4161/derm.19667] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
26 Krane A, Terhorst L, Bovbjerg DH, Scheier MF, Kucinski B, Geller DA, Marsh W, Tsung A, Steel JL. Putting the life in lifestyle: Lifestyle choices after a diagnosis of cancer predicts overall survival. Cancer 2018;124:3417-26. [PMID: 29975412 DOI: 10.1002/cncr.31572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Linder S, Boström L, Nilsson B. Pancreatic carcinoma incidence and survival in Sweden in 1980-2000: a population-based study of 16,758 hospitalized patients with special reference to different therapies. Eur J Surg Oncol. 2007;33:616-622. [PMID: 17317081 DOI: 10.1016/j.ejso.2006.12.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
28 Webber NP, Sharma S, Grossmann AH, Shaaban A, Jones KB, Layfield LJ, Randall RL. Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases. J Clin Oncol 2010;28:e545-9. [PMID: 20713877 DOI: 10.1200/JCO.2010.28.6153] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Eguia E, Aranha GV, Abood G, Godellas C, Kuo PC, Baker MS. Do high-volume centers mitigate complication risk and reduce costs associated with performing pancreaticoduodenectomy in ethnic minorities? Am J Surg 2021;222:153-8. [PMID: 33309036 DOI: 10.1016/j.amjsurg.2020.11.025] [Reference Citation Analysis]
30 Isherwood J, Bilku D, Metcalfe MS, Dennison AR, Garcea G. Treatment Access and Survival Amongst British Asians with Pancreatic Cancer. World J Surg 2017;41:546-51. [PMID: 27600708 DOI: 10.1007/s00268-016-3707-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Noel M, Fiscella K. Disparities in Pancreatic Cancer Treatment and Outcomes. Health Equity. 2019;3:532-540. [PMID: 31663065 DOI: 10.1089/heq.2019.0057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
32 Molina G, Clancy TE, Tsai TC, Lam M, Wang J. Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma. Ann Surg Oncol 2021;28:1088-96. [PMID: 32651695 DOI: 10.1245/s10434-020-08717-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Luo J, Xiao L, Wu C, Zheng Y, Zhao N. The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004-2009. PLoS One. 2013;8:e76052. [PMID: 24130758 DOI: 10.1371/journal.pone.0076052] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 4.7] [Reference Citation Analysis]
34 Dagan E. Predominant Ashkenazi BRCA1/2 Mutations in Families with Pancreatic Cancer. Genetic Testing 2008;12:267-71. [DOI: 10.1089/gte.2007.0101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
35 He W, Zhao H, Chan W, Lopez D, Shroff RT, Giordano SH. Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Surgery. 2015;158:1226-1234. [PMID: 26138347 DOI: 10.1016/j.surg.2015.04.031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
36 Sharp L, Carsin A, Cronin-fenton D, O’driscoll D, Comber H. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. European Journal of Cancer 2009;45:1450-9. [DOI: 10.1016/j.ejca.2009.01.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
37 Shah AP, Strauss JB, Abrams RA. Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer. Am J Clin Oncol 2010;33:101-6. [PMID: 19636239 DOI: 10.1097/COC.0b013e31819171b9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
38 Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer 2011;104:300-7. [PMID: 21179034 DOI: 10.1038/sj.bjc.6606052] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
39 Zeni LB, Russi RF, Fialho AF, Fonseca AL, Sombrio LS, Rocha IC. Morbidity and mortality of pancreatic tumors undergoing surgical treatment. Arq Bras Cir Dig 2014;27:275-9. [PMID: 25626938 DOI: 10.1590/S0102-67202014000400011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
40 Yang SH, Guo JC, Yeh KH, Tien YW, Cheng AL, Kuo SH. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. J Gastroenterol Hepatol 2016;31:2004-12. [PMID: 27059987 DOI: 10.1111/jgh.13395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
41 Bliton JN, Parides M, Muscarella P, Papalezova KT, In H. Understanding Racial Disparities in Gastrointestinal Cancer Outcomes: Lack of Surgery Contributes to Lower Survival in African American Patients. Cancer Epidemiol Biomarkers Prev 2021;30:529-38. [PMID: 33303644 DOI: 10.1158/1055-9965.EPI-20-0950] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Shah A, Chao KS, Ostbye T, Castleberry AW, Pietrobon R, Gloor B, Clary BM, White RR, Worni M. Trends in racial disparities in pancreatic cancer surgery. J Gastrointest Surg 2013;17:1897-906. [PMID: 24002757 DOI: 10.1007/s11605-013-2304-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
43 Ma SJ, Oladeru OT, Miccio JA, Iovoli AJ, Hermann GM, Singh AK. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer. JAMA Netw Open 2019;2:e199126. [PMID: 31411712 DOI: 10.1001/jamanetworkopen.2019.9126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
44 Saadat LV, Chou JF, Gonen M, Soares KC, Kingham TP, Varghese AM, Jarnagin WR, D'Angelica MI, Drebin JA, O'Reilly EM, Wei AC. Treatment patterns and survival in patients with early-onset pancreatic cancer. Cancer 2021;127:3566-78. [PMID: 34228820 DOI: 10.1002/cncr.33664] [Reference Citation Analysis]
45 Abraham A, Al-Refaie WB, Parsons HM, Dudeja V, Vickers SM, Habermann EB. Disparities in pancreas cancer care. Ann Surg Oncol. 2013;20:2078-2087. [PMID: 23579872 DOI: 10.1245/s10434-012-2843-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
46 Teiblum S, Thygesen LC, Johansen C. Sixty-One Years of Pancreatic Cancer in Denmark From 1943 to 2003: A Nationwide Study. Pancreas 2009;38:374-8. [DOI: 10.1097/mpa.0b013e31819b71ae] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
47 Akhtar-Danesh GG, Finley C, Akhtar-Danesh N. Long-term trends in the incidence and relative survival of pancreatic cancer in Canada: A population-based study. Pancreatology. 2016;16:259-265. [PMID: 26804003 DOI: 10.1016/j.pan.2015.12.180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
48 Wakabayashi H, Nishiyama Y, Otani T, Sano T, Yachida S, Okano K, Izuishi K, Suzuki Y. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008; 14(1): 64-69 [PMID: 18176963 DOI: 10.3748/wjg.14.64] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
49 Kirkegård J, Ladekarl M, Fristrup CW, Hansen CP, Sall M, Mortensen FV. Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. PLoS One 2018;13:e0202486. [PMID: 30114213 DOI: 10.1371/journal.pone.0202486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
50 Murphy MM, Simons JP, Hill JS, Mcdade TP, Chau Ng S, Whalen GF, Shah SA, Harrison LH, Tseng JF. Pancreatic resection: A key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer 2009;115:3979-90. [DOI: 10.1002/cncr.24433] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
51 Baig Z, Abu-Omar N, Khan R, Verdiales C, Frehlick R, Shaw J, Wu FX, Luo Y. Prognosticating Outcome in Pancreatic Head Cancer With the use of a Machine Learning Algorithm. Technol Cancer Res Treat 2021;20:15330338211050767. [PMID: 34738844 DOI: 10.1177/15330338211050767] [Reference Citation Analysis]
52 Oh SY, Edwards A, Mandelson MT, Lin B, Dorer R, Helton WS, Kozarek RA, Picozzi VJ. Rare long-term survivors of pancreatic adenocarcinoma without curative resection. World J Gastroenterol 2015; 21(48): 13574-13581 [PMID: 26730170 DOI: 10.3748/wjg.v21.i48.13574] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
53 Imaoka H, Kou T, Tanaka M, Egawa S, Mizuno N, Hijioka S, Hara K, Yazumi S, Shimizu Y, Yamao K. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. Eur J Cancer. 2016;54:96-103. [PMID: 26741729 DOI: 10.1016/j.ejca.2015.11.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
54 Bregar AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, Schorge JO, Rice LW, Del Carmen MG. Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis. Gynecol Oncol 2017;145:114-21. [PMID: 28159409 DOI: 10.1016/j.ygyno.2017.01.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
55 Kongkam P, Benjasupattananun P, Taytawat P, Navicharoen P, Sriuranpong V, Vajragupta L, Klaikaew N, Ridtitid W, Treeprasertsuk S, Rerknimitr R. Pancreatic cancer in an Asian population. Endosc Ultrasound. 2015;4:56-62. [PMID: 25789286 DOI: 10.4103/2303-9027.151361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
56 Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol. 2011;174:1373-1381. [PMID: 22047824 DOI: 10.1093/aje/kwr267] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
57 Mönkemüller K, Fry LC, Malfertheiner P. Pancreatic Cancer Is ‘Always Non-Resectable’. Dig Dis 2007;25:285-8. [DOI: 10.1159/000103904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
58 Gawron AJ, Gapstur SM, Fought AJ, Talamonti MS, Skinner HG. Sociodemographic and tumor characteristics associated with pancreatic cancer surgery in the United States. J Surg Oncol. 2008;97:578-582. [PMID: 18452217 DOI: 10.1002/jso.21040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
59 Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, Testi W, Tanzini G, Francini G. Biweekly Triple Combination Chemotherapy with Gemcitabine, Oxaliplatin, Levofolinic Acid and 5-Fluorouracil (GOLF) Is a Safe and Active Treatment for Patients with Inoperable Pancreatic Cancer. Journal of Chemotherapy 2013;20:119-25. [DOI: 10.1179/joc.2008.20.1.119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
60 Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. Cancer J. 2012;18:477-484. [PMID: 23187833 DOI: 10.1097/ppo.0b013e3182756803] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
61 Segel JE, Hollenbeak CS, Gusani NJ. Rural‐Urban Disparities in Pancreatic Cancer Stage of Diagnosis: Understanding the Interaction With Medically Underserved Areas. The Journal of Rural Health 2020;36:476-83. [DOI: 10.1111/jrh.12498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Bahardoust M, Abyazi MA, Emami SA, Ghadimi P, Khodabandeh M, Mahmoudi F, Hosseinzadeh R, Heiat M, Agah S. Predictors of survival rate in patients with pancreatic cancer: A multi-center analytical study in Iran. Cancer Rep (Hoboken) 2021;:e1547. [PMID: 34494396 DOI: 10.1002/cnr2.1547] [Reference Citation Analysis]
63 Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8-18. [PMID: 25726048 DOI: 10.1053/j.seminoncol.2014.12.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 10.0] [Reference Citation Analysis]
64 Cronin-Fenton DP, Erichsen R, Mortensen FV, Dikinis S, Nørgaard M, Jacobsen J. Pancreatic cancer survival in central and northern Denmark from 1998 through 2009: a population-based cohort study. Clin Epidemiol 2011;3 Suppl 1:19-25. [PMID: 21814466 DOI: 10.2147/CLEP.S20611] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
65 Cervantes A, Waymouth EK, Petrov MS. African-Americans and Indigenous Peoples Have Increased Burden of Diseases of the Exocrine Pancreas: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2019;64:249-261. [PMID: 30259278 DOI: 10.1007/s10620-018-5291-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
66 Bouvier AM, Bossard N, Colonna M, Garcia-Velasco A, Carulla M, Manfredi S; GRELL EUROCARE-5 Working Group. Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev 2017;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S63-9. [PMID: 28005607 DOI: 10.1097/CEJ.0000000000000303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
67 Murphy MM, Simons JP, Ng SC, McDade TP, Smith JK, Shah SA, Zhou Z, Earle CC, Tseng JF. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:2968-2977. [PMID: 19669839 DOI: 10.1245/s10434-009-0656-5] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 6.0] [Reference Citation Analysis]
68 Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL. Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol. 2008;15:1948-1958. [PMID: 18414951 DOI: 10.1245/s10434-008-9905-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
69 Terashima T, Yamashita T, Sakai A, Ohta H, Hinoue Y, Toya D, Kawai H, Yonejima M, Urabe T, Noda Y, Mizukoshi E, Kaneko S. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Jpn J Clin Oncol. 2018;48:966-973. [PMID: 30256958 DOI: 10.1093/jjco/hyy132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
70 Ng W, Jacob S, Delaney G, Do V, Barton M. Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care. Gastroenterol Res Pract 2015;2015:753480. [PMID: 25883645 DOI: 10.1155/2015/753480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-180. [PMID: 17667493 DOI: 10.1097/sla.0b013e3180691579] [Cited by in Crossref: 354] [Cited by in F6Publishing: 143] [Article Influence: 23.6] [Reference Citation Analysis]
72 Shavers VL, Harlan LC, Jackson M, Robinson J. Racial/ethnic patterns of care for pancreatic cancer. J Palliat Med 2009;12:623-30. [PMID: 19594347 DOI: 10.1089/jpm.2009.0036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]